pipette
ESEspañol

An LRH-1 agonist reverses hepatic metabolic dysfunction in obesity

S. G. Mays, A. R. Cuevas, R. M. Spurlin, R. Polavarapu, C.-y. Chen, Z. Hou, M. L. Cato, R. Swinger, E. J. Millings, A. R. Flynn, D. Bhowmik, H. Zecca, W.-Y. Hsiao, S. M. Abraham, A. M. Johnson, N. T. Jui, E. A. Ortlund, J. W. Calvert

PreprintReal-world use

In the authors' words

Liver receptor homolog-1 (LRH-1; NR5A2) is a nuclear receptor that controls metabolic gene programs important for liver health. Here, we address two challenges with dissecting ligand-driven LRH-1 metabolism in vivo. First, we generate ME610, a potent LRH-1 agonist with favorable pharmacokinetic properties. Second, we engineer Nr5a2humLBD mice, edited to recapitulate the ligand response of the human receptor. ME610 dose-dependently induces LRH-1 target genes and reduces triglycerides in livers of Nr5a2humLBD mice. In a mouse model of diet-induced obesity (DIO), ME610 dramatically improves insulin sensitivity and reduces liver fat. Multi-omics integration of transcriptomics, lipidomics, and metabolomics data demonstrates a coordinated reversal of DIO-induced hepatic metabolic stress via changes in lipid, amino acid, and energy metabolism, with peroxisomal lipid metabolism emerging as a central process correlated to efficacy. These studies uncover new pathways through which LRH-1 regulates metabolism and demonstrate the therapeutic potential of synthetic LRH-1 agonists in obesity-associated metabolic diseases.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, November 4. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.28.761933